377 related articles for article (PubMed ID: 10092957)
1. Clinical pharmacokinetics of docetaxel.
Clarke SJ; Rivory LP
Clin Pharmacokinet; 1999 Feb; 36(2):99-114. PubMed ID: 10092957
[TBL] [Abstract][Full Text] [Related]
2. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance.
Hirth J; Watkins PB; Strawderman M; Schott A; Bruno R; Baker LH
Clin Cancer Res; 2000 Apr; 6(4):1255-8. PubMed ID: 10778948
[TBL] [Abstract][Full Text] [Related]
3. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and metabolism of Taxotere (docetaxel).
Bruno R; Sanderink GJ
Cancer Surv; 1993; 17():305-13. PubMed ID: 7907950
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the linearity of docetaxel pharmacokinetics.
McLeod HL; Kearns CM; Kuhn JG; Bruno R
Cancer Chemother Pharmacol; 1998; 42(2):155-9. PubMed ID: 9654116
[TBL] [Abstract][Full Text] [Related]
6. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
Gustafson DL; Long ME; Zirrolli JA; Duncan MW; Holden SN; Pierson AS; Eckhardt SG
Cancer Chemother Pharmacol; 2003 Aug; 52(2):159-66. PubMed ID: 12759775
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of docetaxel and cisplatin in previously untreated patients with advanced non-small-cell lung cancer.
Millward MJ; Zalcberg J; Bishop JF; Webster LK; Zimet A; Rischin D; Toner GC; Laird J; Cosolo W; Urch M; Bruno R; Loret C; James R; Blanc C
J Clin Oncol; 1997 Feb; 15(2):750-8. PubMed ID: 9053501
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of Taxotere: five-day schedule.
Pazdur R; Newman RA; Newman BM; Fuentes A; Benvenuto J; Bready B; Moore D; Jaiyesimi I; Vreeland F; Bayssas MM
J Natl Cancer Inst; 1992 Dec; 84(23):1781-8. PubMed ID: 1359154
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of the taxanes.
Dorr RT
Pharmacotherapy; 1997; 17(5 Pt 2):96S-104S. PubMed ID: 9322876
[TBL] [Abstract][Full Text] [Related]
10. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel.
Engels FK; Ten Tije AJ; Baker SD; Lee CK; Loos WJ; Vulto AG; Verweij J; Sparreboom A
Clin Pharmacol Ther; 2004 May; 75(5):448-54. PubMed ID: 15116057
[TBL] [Abstract][Full Text] [Related]
11. Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion.
Extra JM; Rousseau F; Bruno R; Clavel M; Le Bail N; Marty M
Cancer Res; 1993 Mar; 53(5):1037-42. PubMed ID: 8094996
[TBL] [Abstract][Full Text] [Related]
12. Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.
van Zuylen L; Verweij J; Nooter K; Brouwer E; Stoter G; Sparreboom A
Clin Cancer Res; 2000 Jul; 6(7):2598-603. PubMed ID: 10914699
[TBL] [Abstract][Full Text] [Related]
13. Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol.
Yamamoto N; Tamura T; Kamiya Y; Sekine I; Kunitoh H; Saijo N
J Clin Oncol; 2000 Jun; 18(11):2301-8. PubMed ID: 10829051
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials.
Bruno R; Riva A; Hille D; Lebecq A; Thomas L
Am J Health Syst Pharm; 1997 Dec; 54(24 Suppl 2):S16-9. PubMed ID: 9435928
[TBL] [Abstract][Full Text] [Related]
15. Early clinical studies with docetaxel. Docetaxel Investigators Group.
Aapro M; Bruno R
Eur J Cancer; 1995; 31A Suppl 4():S7-10. PubMed ID: 7577102
[TBL] [Abstract][Full Text] [Related]
16. The international experience with docetaxel in the treatment of breast cancer.
Ravdin PM
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):38-42. PubMed ID: 9110341
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel.
Cortes JE; Pazdur R
J Clin Oncol; 1995 Oct; 13(10):2643-55. PubMed ID: 7595719
[TBL] [Abstract][Full Text] [Related]
18. Preclinical pharmacokinetics of paclitaxel and docetaxel.
Sparreboom A; van Tellingen O; Nooijen WJ; Beijnen JH
Anticancer Drugs; 1998 Jan; 9(1):1-17. PubMed ID: 9491787
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel in combination with platinums in patients with advanced non-small-cell lung cancer.
Belani CP
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):42-5. PubMed ID: 9364542
[TBL] [Abstract][Full Text] [Related]
20. The role of taxanes in the treatment of breast cancer.
Capri G; Tarenzi E; Fulfaro F; Gianni L
Semin Oncol; 1996 Feb; 23(1 Suppl 2):68-75. PubMed ID: 8614849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
